93

R IEW

PATENT
ATTORNEY DOCKET: 62732.000105

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number	:	09/591,500	Confirmation No.: 1642
Applicant	:	Gary R. PASTERNACK et al.	
Filed	:	June 12, 2000	
Title	:	GENE FAMILY WITH TRANSFORMATION MODULATING ACTIVITY	
TC/Art Unit	:	1642	
Examiner:	:	Misook Yu	
Docket No.	:	62732.000105	
Customer No.	:	**21967**	

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, applicants are submitting herewith copies of the references listed on the attached Form PTO-SB/08A (modified) for consideration and to be made of record herein by the U.S. Patent and Trademark Office in the above-captioned application.

Applicants also wish to bring to the Examiner's attention the following published co-pending U.S. Patent Application:

> U.S. Patent Application Serial No. 10/273,334, filed October 18, 2002,
> U.S. Patent Application Publication No. US20030129631,
> Inventors - Pasternack *et al.*

A copy of the co-pending patent application publication is provided herewith.

Applicants also provide herewith for the Examiner's consideration copies of the International Search Report dated 07/02/1999 for International Application No. PCT/US98/26433 and the International Preliminary Examination Report for PCT/US98/26433. An indication of consideration of the co-pending published patent application, the International

Search Report and the International Preliminary Examination Report by the Examiner would be appreciated.

This Information Disclosure Statement (IDS) is not to be construed as a representation that a search has, or has not, been conducted or that no better art exists. The filing of this IDS is not to be construed as admission that the information cited in the IDS is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b). In considering the cited references, it may be noted by the Examiner that certain of the references may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited references. Any such markings were either present on the copies of the cited references obtained by the associated individuals, or were made thereon during the study of the references by the associated individuals.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form SB/08A with the Examiner's initials in the left column in accordance with MPEP 609 are respectfully requested.

In accordance with 37 C.F.R. § 1.97(b), this Second Supplemental Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action after the filing of the RCE under 37 C.F.R. §1.114. Therefore, it is respectfully submitted that no additional fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.In the event any variance exists between the amount enclosed and the Patent Office charges, please charge or credit any difference to the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: October 14, 2004

By: 

Robert C. Lampe, III
Registration No. 51,914

Hunton & Williams LLP
Intellectual Property Department

1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

RCL/sdw

PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet	1	of	9

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US 4874845	10-17-1989	Saito et al.	
	2.	US 4889818	12-26-1989	Gelfand et al.	
	3.	US 5200313	04-06-1993	Carrico	
	4.	US 5527884	06-18-1996	Russell et al.	
	5.	US 5756676	05-26-1998	Pasternack	
	6.	US 5874234	02-23-1999	Pasternack	
	7.	US 6040173	03-21-2000	Pasternack	
	8.	US 20030129631	07-10-2003	Pasternack et al	

FOREIGN PATENT DOCUMENTS

*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT Country Code:	Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION YES	TRANSLATION NO
	9.	WO	99/29906	06-17-1999	Pasternack et al.		☐	☐
	10.	WO	92/02554	02-20-1992	Pasternack		☐	☐
	11.	EPO	0375408	06-27-1990	Hogan et al		☐	☐
							☐	☐

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet 2 of 9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	12.	(ABSTRACT) ANDERSON et al., *"Tissue Specific Isoforms of Erythroid Protein 4.1,"* Spectrin-Associated Proteins, item no. 2032, J. Cell Biol., 103: page 542a.		
	13.	(ABSTRACT) PASTERNACK et al., *"Protein 4.1 as a Myosin Binding and Modulating Protein: Insights into a new functional class of proteins,"* Cellular and Molecular Biology of Normal and Abnormal Erythroid Membranes, J. Cell Biochem,. Suppl. 13, Part B, pp 209		
	14.	KRAUSS et al., "Structural protein 4.1 is located in mammalian centrosomes," Proc. Natl. Acad. Sci. USA 94: 7297-7302 (1997), the National Academy of Sciences.		
	15.	CHEN, et al., 1989, "Phosphorylation of Retinoblastoma Gene Product is Modulated During the Cell Cycle and Cellular Differentiation," Cell, 58:1193-1198, Cell Press.		
	16.	COOPER, et al., "RB and the Cell Cycle: Entrance or Exit?" 1989, Cell, 58:1009-1011, Cell Press.		
	17.	FEUERSTEIN, et al., 1988, "The Nuclear Matrix Protein, Numatrin (B23), Is Associated With Growth Factor-Induced Mitogenesis in Swiss 3T3 Fibroblasts and with T Lymphocyte Proliferation Stimulated by Lectins and Anti-T Cell Antigen Receptor Antibody," J. Cell Biol., 107:1629-1642, the Rockefeller University Press.		
	18.	GERDES, et al., 1984, "Cell Cycle Analysis of a Cell Proliferation-Associated Human Nuclear Antigen Defined by the Monoclonal Antibody Ki-67," J. Immunol., 133:1710-1715, the American Association of Immunologists.		
	19.	GOMEZ-MARQUEZ, et al., 1989, "The Expression of Prothymosin α Gene in T Lymphocytes and Leukemic Lymphoid Cells Is Tied to Lymphocyte Proliferation," J. Biol. Chem., 264:8451-8454, The American Society for Biochemistry and Molecular Biology, Inc.		

EXAMINER SIGNATURE | DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet	3	of	9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	20.	MORLA, et al., 1989, "Reversible Tyrosine Phosphorylation of cdc2: Dephosphorylation Accompanies Activation During Entry into Mitosis," Cell, 58:193-203, Cell Press.		
	21.	SHAWVER, et al., 1989, "Platelet-Derived Growth Factor Induces Phosphorylation of a 64-kDa Nuclear Protein," J. Biol. Chem., 264:1046-1050, the American Society for Biochemistry and Molecular Biology, Inc.		
	22.	TAN, et al., 1987, "Autoantibody to the Proliferating Cell Nuclear Antigen Neutralizes the Activity of the Auxiliary Protein for DNA Polymerase Delta," Nucleic Acids Res., 15:9299-9308, IRL Press Limited, Oxford, England.		
	23.	WHELLY, et al., 1977, "Relationship Between Cell Proliferation, Chromatin Template Activity And Accumulation of Nuclear Proteins," Cell Biol. Int. Rep., 1:13-21.		
	24.	ACKERMAN, et al., 1985, "Phosphorylation of DNA Topoisomerase II by Casein Kinase II: Modulation of Eukaryotic Topoisomerase II Activity *in vitro*," Proc. Natl. Acad. Sci., USA, 82:3164-3168.		
	25.	ACKERMAN, et al., 1989, "Regulation of Casein Kinase II Activity by Epidermal Growth Factor in Human A-431 Carcinoma Cells," J. Biol. Chem., 264:11958-11965, the American Society for Biochemistry and Molecular Biology, Inc.		
	26.	DUCEMAN, et al., 1981, "Activation of Purified Hepatoma RNA Polymerase I by Homologous Protein Kinase NII, " J. Biol. Chem., 256:10755-10758.		
	27.	DURBAN, et al., 1985, "Topoisomerase I Phosphorylation *in vitro* and in Rapidly Growing Novikoff Hepatoma Cells," EMBO J., 4:2921-2926, IRL Press Limited, Oxford, England.		
	28.	FRIEDMAN, et al., 1985, "Nuclear Protein Phosphorylation in Isolated Nuclei from HeLa Cells. Evidence that ^{32}P Incorporation from [γ- ^{32}P] GTP is Catalyzed by Nuclear Kinase II," Biochem. Biophys. Acta, 847:165-176, Elsevier Science Publishers B.V.		
	29.	HOLCOMB, et al., 1984, "Phosphorylation of the C-Proteins of HeLa Cell hnRNP Particles," J. Biol. Chem., 259:31-40, the American Society of Biological Chemists, Inc.		
	30.	KLARLUND, et al., 1988, "Insulin-Like Growth Factor I and Insulin Rapidly Increase Casein Kinase II Activity in BALB/c 3T3 Fibroblasts," J. Biol. Chem., 263:15872-15875, the American Society for Biochemistry and Molecular Biology, Inc.		

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet 4 of 9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	31.	MATTHEWS, et al., 1984, "Nuclear Protein Kinases," Mol. Cell. Biochem., 59:81-99, Martinus Nijhoff Publishers, Boston, Mass., Printed in the Netherlands.		
	32.	PFAFF, et al., 1988, "Casein Kinase II Accumulation in the Nucleolus and Its Role in Nucleolar Phosphorylation," Biochem. Biophys. Acta, 969:100-109, Elsevier Science Publishers B.V.		
	33.	SOMMERCORN, et al., 1987, 1 "Activation of Casein Kinase II in Response to Insulin and to Epidermal Growth Factor," Proc. Natl. Acad. Sci., USA, 84:8834-8838.		
	34.	STETLER, et al., 1982, "Phosphorylation of Deoxyribonucleic Acid Dependent RNA Polymerase II by Nuclear Protein Kinase NII: Mechanism of Enhanced Ribonucleic Acid Synthesis," Biochemistry, 21:3721-3728, American Chemical Society.		
	35.	WALTON, et al., 1985, "Phosphorylation of High Mobility Group Protein 14 by Casein Kinase II," J. Biol. Chem., 260:4745-4750, the American Society of Biological Chemists, Inc.		
	36.	ELIYAHU, et al., 1989, "Wild-Type p53 Can Inhibit Oncogene-Mediated Focus Formation," Proc. Natl. Acad. Sci., USA, 86:8763-8767.		
	37.	GINSBERG, et al., 1991, "Transfected Mouse c-jun Can Inhibit Transformation of Primary Rat Embryo Fibroblasts," Oncogene, 6:669-672, Macmillan Press Limited.		
	38.	LAND, et al., 1983, "Tumorigenic Conversion of Primary Embryo Fibroblasts Requires At Least Two Cooperating Oncogenes," Nature, 304:596-602, Macmillan Journals Ltd.		
	39.	MAKELA, et al., 1992, "Alternative Forms of Max as Enhancers or Suppressors of Myc-Ras Cotransformation," Science, 256:373-377.		
	40.	RESAR, et al., 1993, "B-Myc Inhibits Neoplastic Transformation and Transcriptional Activation by c-Myc," Mol. Cell. Biol., 13:1130-1136, American Society for Microbiology.		
	41.	VAN DEN HEUVEL, et al., 1993, "Large E1B Proteins of Adenovirus Types 5 and 12 Have Different Effects on p53 and Distinct Roles in Cell Transformation," J. Virol., 67:5226-5234, American Society for Microbiology.		

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet 5 of 9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	42.	YEHIELY, et al., 1992, "The Gene for the Rat Heat-Shock Cognate, hsc 70, Can Suppress Oncogene-Mediated Transformation," Cell. Growth Diff., 3:803-809.		
	43.	ALNEMRI, et al., 1992, "Overexpressed Full-Length Human BCL2 Extends the Survival of Baculovirus-Infected Sf9 Insect Cells," Proc. Natl. Acad. Sci., USA, 89:7295-7299.		
	44.	BUTTYAN, R., 1991, "Genetic Response of Prostate Cells to Androgen Deprivation: Insights Into the Cellular Mechanism of Apoptosis," in Apoptosis: The Molecular Basis of Cell Death, J. Inglis, et al, eds., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, pp. 157-173.		
	45.	DE JONG, et al., 1994, "Subcellular Localization of the bcl-2 Protein in Malignant and Normal Lymphoid Cells," Cancer Res., 54:256-260.		
	46.	GERSCHENSON, et al., 1991, "Apoptosis and Cell Proliferation are Terms of the Growth Equation," in Apoptosis: The Molecular Basis of Cell Death, J. Inglis, et al, eds., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, pp. 175-192.		
	47.	HOCKENBERY, et al., 1991, "BCL2 Protein is Topographically Restricted in Tissues Characterized by Apoptotic Cell Death," Proc. Natl. Acad. Sci., USA, 88:6961-6965.		
	48.	KERR, et al., 1991, "Definition and Incidence of Apoptosis: An Historical Perspective," in Apoptosis: The Molecular Basis of Cell Death, J. Inglis, et al, eds., Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, pp. 5-29.		
	49.	MARTIN, et al., 1994, "Dicing With Death: Dissecting the Components of the Apoptosis Machinery," Trends Biochem. Sci., 19:26-30.		
	50.	WAGNER, et al., 1993, "Myc-Mediated Apoptosis is Blocked By Ectopic Expression of Bcl-2," Mol. Cell. Biol., 13:2432-2440, American Society for Microbiology.		
	51.	BRIGGS, et al., 1992, "Nuclear Morphometry for Prediction of Metastatic Potential in Early Squamous Cell Carcinoma of the Floor of the Mouth," Arch. Otolaryngol Head. Neck. Surg., 118:531-533.		
	52.	DAWSON, et al., 1991, "Nuclear Grading of Breast Carcinoma by Image Analysis. Classification by Multivariate and Neural Network Analysis," Am. J. Clin. Pathol., 95:S29-S37.		

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet	6	of	9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	53.	DIAMOND, et al., 1982 "A New Method To Assess Metastatic Potential of Human Prostate Cancer: Relative Nuclear Roundness," J. Urol., 128:729-734, the Williams & Wilkins Co., Printed in the U.S.		
	54.	DIAMOND, et al., 1982, "Computerized Image Analysis of Nuclear Shape as a Prognostic Factor for Prostatic Cancer," The Prostate, 3:321-332, Alan R. Liss, Inc.		
	55.	DRESCHER, et al., 1993, "Prognostic Significance of DNA Content and Nuclear Morphology in Borderline Ovarian Tumors," Gynecol. Oncol., 48:242-246, Academic Press Inc.		
	56.	EPSTEIN, et al., 1984, "Nuclear Roundness Factor. A Predictor of Progression in Untreated State A2 Prostate Cancer," Cancer, 54:1666-1671.		
	57.	FLEMING, et al., 1990, "Image Analysis Cytometry of Dysplastic Nevi," J. Invest. Dermatol., 95:287-291, the Society for Investigative Dermatology, Inc.		
	58.	GALERA-DAVIDSON, et al., 1990, "Cytophotometric DNA Measurements in Medullary Thyroid Carcinoma," Cancer, 65:2255-2260.		
	59.	HILL, et al., 1989, "The Proportion of Stem Cells in Murine Tumors," Int. J. Radiat. Oncol. Biol. Phys., 16:513-518, Pergamon Press Inc., Printed in the U.S.		
	60.	MURPHY, et al., 1990, "Nuclear Shape Analysis for Assessment of Prognosis in Renal Cell Carcinoma," J. Urol., 143:1103-1107, American Urological Association, Inc.		
	61.	PARTIN, et al., 1990, "Nuclear Morphometry as a Predictor of Response to Therapy in Wilms Tumor: A Preliminary Report," J. Urol., 144:952-954, American Urological Association, Inc.		
	62.	PIENTA, et al., 1991, "Correlation of Nuclear Morphometry with Progression of Breast Cancer," Cancer, 68:2012-2016.		
	63.	RICKAERT, et al., 1992, "Computerized Morphonuclear Characteristics and DNA Content of Adenocarcinoma of the Pancreas, Chronic Pancreatitis, and Normal Tissues: Relationship with Histopathologic Grading," Hum. Pathol., 23:1210-1215, W.B. Saunders Co.		

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet	7	of	9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	64.	VAN ETTEN,et al., 1989, "The Mouse Type IV c-abl Gene Product Is a Nuclear Protein, and Activation of Transforming Ability is Associated with Cytoplasmic Localization," Cell 58:669-678, Cell Press.		
	65.	WEGER, et al., 1992, "Morphometry and Prognosis in Cancer of the Pancreatic Head," Pathol. Res. Pract., 188:764-769, Gustav Fischer Verlag, Stuttgart.		
	66.	ANDERSON, et al., 1988, "Tissue-Specific Analogues of Erythrocyte Protein 4.1 Retain Functional Domains," J. Cell. Biochem., 37:269-284, Alan R. Liss, Inc.		
	67.	ASTER, et al., 1984, "Identification of Spectrin and Protein 4.1-Like Proteins In Mammalian Lens," Biochem. Biophys. Res. Comm., 119:726-734, Academic Press Inc.		
	68.	ASTER, et al., 1986, "The 4.1-Like Proteins of the Bovine Lens: Spectrin-binding Proteins Closely Related in Structure to Red Blood Cell Protein 4.1" J. Cell Biol., 103:115-122, the Rockefeller University Press.		
	69.	BOURGUIGNON, et al., 1986, "Lymphoma Thy-1 Glycoprotein Is Linked to the Cytoskeleton via a 4.1-Like Protein," J. Cell Biol., 103:2529-2540, the Rockefeller University Press.		
	70.	CHO, et al., 1988, "Antibodies to Cytoskeletal Erythrocyte Protein 4.1 Recognizes Domain Specific Proteins of the Hepatocyte Plasma Membrane in Isolated Hepatocyte Couplets," Gastroenterology, 94:A529.		
	71.	COHEN, et al., 1982, "A Protein Immunologically Related To Erythrocyte Band 4.1 is Found On Stress Fibres of Non-Erythroid Cells," Nature, 299:648-650, Macmillan Journals Ltd.		
	72.	CONSTANTINESCU, et al., 1986, "Immunological Detection of An Analogue of the Erythroid Protein 4.1 In Endothelial Cells," Cell Biol. Intl. Rept., 10:861-868.		
	73.	CORREAS, Isabel, 1991, "Characterization of Isoforms of Protein 4.1 Present in the Nucleus," Biochem. J., 279:581-585, Printed in Great Britain.		
	74.	DAVIES, et al., 1985, "Platelets Contain Proteins Immunologically Related to Red Cell Spectrin and Protein 4.1," Blood, 65:52-59, Grune & Stratton Inc.		
	75.	DE CESARIS, et al., 1989, "Spectrin, Fodrin and Protein 4.1-Like Proteins In Differentiating Rat Germ Cells," Differentiation, 41:216-222, Springer-Verlag.		

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08A (10/01) (modified)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

Sheet 8 of 9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	76.	GOODMAN, et al., 1984, "Identification and Location of Brain Protein 4.1," Science, 224:1433-1436.		
	77.	SPENCER, et al., 1990, "Membrane Skeleton Protein 4.1 in Developing Xenopus: Expression In Postmitotic Cells of the Retina," Developmental Biology, 139:279-291, Academic Press Inc.		
	78.	SPIEGEL, et al., 1984, "An Analogue of the Erythroid Membrane Skeletal Protein 4.1 In Nonerythroid Cells," J. Cell Biol., 99:886-893, the Rockefeller University Press.		
	79.	STEVENSON, et al., 1989, "Fodrin and Band 4.1 in a plasma Membrane-Associated Fraction of Human Neutrophils," Blood, 74:2136-2143, Grune & Stratton Inc.		
	80.	TANG, et al., 1988, "Translation of an mRNA Species Encoding Non-Erythroid Protein 4.1 Generates Two Proteins One of which May Be Localized In The Nucleus," Clin. Res., 36:405a.		
	81.	TANG, et al., 1988, "Expression of Specific Isoforms of Protein 4.1 in Erythroid and Non-Erythroid Tissues," Adv. Exp. Med. Biol., 241:81-95.		
	82.	TANG, et al., 1988, "Selective Expression of an Erythroid-Specific Isoform of Protein 4.1," Proc. Natl. Acad. Sci., USA, 85:3713-3717.		
	83.	TANG, et al., 1990, "Membrane Skeletal Protein 4.1 Of Human Erythroid and Non-Erythroid Cells Is Composed Of Multiple Isoforms With Novel Sizes, Functions and Tissue Specific Expression," Cell. Molec. Biol. of Normal and Abnormal Erythroid Membrane, Alan R. Liss, Inc., New York, pp. 43-59		
	84.	TANG, et al., 1990, "Heterogeneity of mRNA and Protein Products Arising From the Protein 4.1 Gene in Erythroid and Nonerythroid Tissues," J. Cell Biol., 110:617-624, the Rockefeller University Press.		
	85.	ZIPARO, et al., 1986, "Proteins of the Membrane Skeleton In Rat Sertoli Cells," J. Cell Sci., 86:145-154, the Company of Biologists Ltd., Printed in Great Britain.		
	86.	SONODA et al., "Complete Nucleotide Sequence of Human Phosphoribosyl Pyrophosphate Synthetase Subunit I (PRSI) cDNA and a Comparison with Human and Rat PRPS Gene Families," The Journal of Biochemistry. vol. 109., no. 2, pp. 361-364, Feb. 1991.		

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number	09/591,500
Filing Date	June 12, 2000
First Named Inventor	Gary PASTERNACK et al.
Art Unit	1642
Examiner Name	Misook Yu
Attorney Docket Number	62732.000105

OIPE JC174 OCT 14 2004 PATENT & TRADEMARK OFFICE

Sheet 9 of 9

NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION YES	TRANSLATION NO
	87.	ATCC/NIH Repository Catalogue of Human and Mouse DNA/Probes and Libraries, Eighth Edition, pp. 1-58 and 63-70, 1994		
	88.	(ABSTRACT) PASTERNACK et al., "Murine Lymphocytes Express a Novel Form of Protein 4.1", Spectrin-associated Proteins, J. Cell Biol., 103: pp. 543a, item no. 2035		
	89.	(ABSTRACT) PASTERNACK et al., "Cycle-Dependent Variation in the Localization of a Protein Related to Protein 4.1", Nuclear Matrix and Other Proteins, J. Cell Biol., 105: pp. 71a, item no. 392		
	90.	(ABSTRACT) PASTERNACK et al., "Characterization of a Protein 4.1 Analog from Murine B Lymphocytes", Membrane-Mediated Cytotoxicity, J. Cell Biochem., Suppl. 10, Part B, pp. 97, item no. G143		
	91.	JASKULSKI, et al., 1988, "Regulation of the Proliferating Cell Nuclear Antigen Cyclin and Thymidine Kinase mRNA Levels by Growth Factors," J. Biol. Chem., 263:10175-10179, the American Society for Biochemistry and Molecular Biology, Inc.		
	92.	KRAUSS, et al., "Structural Protein 4.1 in the Nucleus of Human Cells: Dynamic Rearrangements during Cell Division," J. Cell Biol., 137:275-289, 1997, the Rockefeller University Press.		
	93.			
	94.			
	95.			
	96.			

EXAMINER SIGNATURE	DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.